Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

Biomarker-informed therapeutic decision-making is the standard of care for malignancies with targetable genetic alterations, including BRAF mutations. It is crucial to ensure clear and consistent ...

Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras ...

Oncogenic activation usually results from point mutation rather than gene rearrangement. The most common BRAF mutation is the T1796A point mutation, resulting in a glutamic acid (E) to valine (V ...

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that greatly extends survival ATC patients with BRAF gene mutations lived a median ...

A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: About Boundless Bio ...

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that greatly extends survival ATC patients with BRAF gene mutations lived a ...

The data suggest that the three-drug combination should replace chemotherapy for one in seven patients with metastatic colorectal cancer who have a BRAF mutation, according to lead investigator ...

Caris Life Sciences has obtained an FDA approval for its MI Cancer Seek tumor profiling assay, unlocking its use as a ...

About 40% of ATC tumors have mutations in the BRAF gene that help drive the cancers' behavior and prognosis. The new trial focused on 42 patients battling a BRAF-mutated ATC. The median overall ...

编者按：2024年10月21-27日，江城武汉迎来一场学术氛围热烈、国际交流深入的会议——国际肝胆胰协会中国分会第九届学术研讨会。《肿瘤瞭望》联合《国际肝病》采访了国际肝胆胰协会（IHPBA）现任主席、法国巴黎AP-HP Paul ...